Investigational drug · Phase 2
AIV007
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neovascular (Wet) Age-Related Macular Degeneration.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "AIV007"
First trial start
2026
Jul 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AIV007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neovascular (Wet) Age-Related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "AIV007" as an intervention, largest first.
AiViva BioPharma, Inc.Industry
NCT07557121 · 35 participants (planned) · Start Jul 1, 2026 · Primary completion Jun 30, 2027
Drug: AIV007; EYLEA® (aflibercept) Injection 2 mg (0.05mL) · For: Neovascular (Wet) Age-Related Macular Degeneration
Sites: Torrance, California; McAllen, Texas
AiViva BioPharma, Inc.Industry
NCT05698329 · 19 participants · Start Mar 2, 2023 · Primary completion Mar 3, 2025
Drug: AIV007 · For: Neovascular Age-related Macular Degeneration; Diabetic Macular Edema; Macular Edema
Sites: Beverly Hills, California; Santa Ana, California; Eugene, Oregon · 6 sites in all
AiViva BioPharma, Inc.Industry
NCT04422899 · 3 participants · Start Aug 28, 2020 · Primary completion Sep 29, 2021
Drug: AIV007 · For: Neovascular Age-related Macular Degeneration
Sites: Huntington Beach, California; Abilene, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Neovascular (Wet) Age-Related Macular Degeneration
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- BAT5906Phase 32 trials
Bio-Thera Solutions · Diabetic Macular Edema (DME), Neovascular (Wet) Age-related Macular Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.